Merger Arbitrage Tool

Filter by Deal Type:

Note: Premium members can sort this table by Profit, Annualized Profit and Closing Date.

  Symbol Announced Date Acquiring
Company
Deal
Type
Clo.
Value
Clo.
Price
Last
Price
Volume Optionable Div. Yield Clo.
Date
Profit Annu.
Profit
PRVL chart 12/15/2020 Eli Lilly and Company (LLY) Special Conditions $895.39 million $26.50 $23.00 4,563,958 Yes N/A 03/31/2021 15.22% 82.90%
Prevail Therapeutics Inc. merger details:

Expected to close in the first quarter of 2021 for a closing value of $895.39 million. Upon completion of the merger, shareholders of Prevail Therapeutics will receive. $22.50 per share in cash payable at closing plus one non-tradable contingent value right worth up to $4.00 per share in cash , for a total consideration of up to $26.50 per share in cash.

Merger Agreement

Prevail Therapeutics Inc. Investor Relations
Eli Lilly and Company Investor Relations

Prevail Therapeutics Inc. Investor Relations

Eli Lilly and Company Investor Relations

Note: Premium members can sort this table by Symbol, Profit, Annualized Profit and Closing Date. Desktop Version

  Symbol Clo. Date Profit Annu. Profit
PRVL chart 03/31/2021 15.22% 82.90%
Prevail Therapeutics Inc. merger details:

Expected to close in the first quarter of 2021 for a closing value of $895.39 million. Upon completion of the merger, shareholders of Prevail Therapeutics will receive. $22.50 per share in cash payable at closing plus one non-tradable contingent value right worth up to $4.00 per share in cash , for a total consideration of up to $26.50 per share in cash.

Merger Agreement

Prevail Therapeutics Inc. Investor Relations
Eli Lilly and Company Investor Relations

Prevail Therapeutics Inc. Investor Relations

Eli Lilly and Company Investor Relations

Only premium members can access all active mergers and acquisitions. Subscribe today.